tetano
Editor, Senior Moderator
Sci Rep
. 2024 Jul 29;14(1):17399.
doi: 10.1038/s41598-024-68433-4. Increased levels of circulating cell-free DNA in COVID-19 patients with respiratory failure
Akihiko Tanaka[SUP] 1 [/SUP], Katsuki Wakayama[SUP] 2 [/SUP], Yosuke Fukuda[SUP] 1 [/SUP], Shin Ohta[SUP] 1 [/SUP], Tetsuya Homma[SUP] 1 [/SUP], Koichi Ando[SUP] 1 3 [/SUP], Yuji Nishihara[SUP] 4 [/SUP], Ryuichi Nakano[SUP] 5 [/SUP], Jing Zhao[SUP] 2 [/SUP], Yuki Suzuki[SUP] 5 [/SUP], Yoji Kyotani[SUP] 2 [/SUP], Hisakazu Yano[SUP] 5 [/SUP], Kei Kasahara[SUP] 4 [/SUP], Kuei-Pin Chung[SUP] 6 7 [/SUP], Hironori Sagara[SUP] 1 [/SUP], Masanori Yoshizumi[SUP] 2 [/SUP], Kiichi Nakahira[SUP] 8 9 [/SUP]
Affiliations
Cell-free DNA (cfDNA) is released from injured cells and aggravates inflammation. Patients with coronavirus disease (COVID-19) often develop pneumonia and respiratory failure, and require oxygen therapy (OT), including mechanical ventilation (MV). It remains unclear whether cfDNA predicts the risk of receiving OT or MV in COVID-19 patients. Therefore, we hypothesized that circulating cfDNA levels could reflect the severity of respiratory failure and determine a therapeutic approach for oxygenation in patients with COVID-19. We analyzed cfDNA levels in serum samples from 95 hospitalized patients with COVID-19 at Showa University Hospital (Tokyo, Japan). cfDNA levels were assessed by measuring the copy numbers of mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) using quantitative real-time PCR (qPCR). Both cf-nDNA and cf-mtDNA levels were negatively correlated with adjusted SpO[SUB]2[/SUB] for FiO[SUB]2[/SUB] (SpO[SUB]2[/SUB]/FiO[SUB]2[/SUB] ratio). Elevated cf-nDNA and cf-mtDNA levels were associated with the requirement for OT or MV during patient admission. Multivariate logistic regression analysis revealed that cf-nDNA and cf-mtDNA levels were independent risk factors for OT and MV. These results suggest that both serum cf-nDNA and cf-mtDNA could serve as useful early biomarkers to indicate the necessity of OT or MV in patients with COVID-19.
. 2024 Jul 29;14(1):17399.
doi: 10.1038/s41598-024-68433-4. Increased levels of circulating cell-free DNA in COVID-19 patients with respiratory failure
Akihiko Tanaka[SUP] 1 [/SUP], Katsuki Wakayama[SUP] 2 [/SUP], Yosuke Fukuda[SUP] 1 [/SUP], Shin Ohta[SUP] 1 [/SUP], Tetsuya Homma[SUP] 1 [/SUP], Koichi Ando[SUP] 1 3 [/SUP], Yuji Nishihara[SUP] 4 [/SUP], Ryuichi Nakano[SUP] 5 [/SUP], Jing Zhao[SUP] 2 [/SUP], Yuki Suzuki[SUP] 5 [/SUP], Yoji Kyotani[SUP] 2 [/SUP], Hisakazu Yano[SUP] 5 [/SUP], Kei Kasahara[SUP] 4 [/SUP], Kuei-Pin Chung[SUP] 6 7 [/SUP], Hironori Sagara[SUP] 1 [/SUP], Masanori Yoshizumi[SUP] 2 [/SUP], Kiichi Nakahira[SUP] 8 9 [/SUP]
Affiliations
- PMID: 39075117
- DOI: 10.1038/s41598-024-68433-4
Cell-free DNA (cfDNA) is released from injured cells and aggravates inflammation. Patients with coronavirus disease (COVID-19) often develop pneumonia and respiratory failure, and require oxygen therapy (OT), including mechanical ventilation (MV). It remains unclear whether cfDNA predicts the risk of receiving OT or MV in COVID-19 patients. Therefore, we hypothesized that circulating cfDNA levels could reflect the severity of respiratory failure and determine a therapeutic approach for oxygenation in patients with COVID-19. We analyzed cfDNA levels in serum samples from 95 hospitalized patients with COVID-19 at Showa University Hospital (Tokyo, Japan). cfDNA levels were assessed by measuring the copy numbers of mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) using quantitative real-time PCR (qPCR). Both cf-nDNA and cf-mtDNA levels were negatively correlated with adjusted SpO[SUB]2[/SUB] for FiO[SUB]2[/SUB] (SpO[SUB]2[/SUB]/FiO[SUB]2[/SUB] ratio). Elevated cf-nDNA and cf-mtDNA levels were associated with the requirement for OT or MV during patient admission. Multivariate logistic regression analysis revealed that cf-nDNA and cf-mtDNA levels were independent risk factors for OT and MV. These results suggest that both serum cf-nDNA and cf-mtDNA could serve as useful early biomarkers to indicate the necessity of OT or MV in patients with COVID-19.